Harmony Biosciences (HRMY)
(Delayed Data from NSDQ)
$27.28 USD
+0.52 (1.94%)
Updated Oct 3, 2025 04:00 PM ET
After-Market: $27.18 -0.10 (-0.37%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HRMY 27.28 +0.52(1.94%)
Will HRMY be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for HRMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HRMY
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
Can Cannabis Stocks Reverse Their Prolonged Downtrend?
HRMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for HRMY
Death Cross appears for HRMY after 1.94% move
Is HRMY ready to make a move? NR7 shows up after dropping 0.59%
New 52 Week Low appears for HRMY after 2.32% move
NR7 appears for HRMY after 0.29% move
Lower Bollinger Band Walk appears for HRMY after 0.47% move